Monday, November 06, 2017 9:19:45 AM
Here's an example. TXMD is up premarket ($1.60) on a .07 narrowing of it's loss and the resubmitting to the FDA for an NDA (6 month time frame) on one of it's drug candidates.
SRNE reports 11/13. We narrowed and beat analyst expectations last quarter by .14. With another narrowing and beat we should see a jump as well. The difference will come in February if the FDA approves our NDA, resubmitted roughly 4 months ago, for the Lidocaine patch. If that occurs the PPS jump will be huge.
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM